LEUKOREDUCTION OF PLATELETS BY PULSED ELECTRIC FIELDS

Information

  • Research Project
  • 6551935
  • ApplicationId
    6551935
  • Core Project Number
    R43HL072692
  • Full Project Number
    1R43HL072692-01
  • Serial Number
    72692
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2002 - 21 years ago
  • Project End Date
    6/30/2003 - 20 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    9/1/2002 - 21 years ago
  • Budget End Date
    6/30/2003 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/30/2002 - 21 years ago

LEUKOREDUCTION OF PLATELETS BY PULSED ELECTRIC FIELDS

DESCRIPTION (provided by applicant): This proposal addresses the utility of pulsed electric field (PEF) technology for leukoreduction of platelet products. Leukocytes in platelet products can cause several complications in recipients of platelet transfusions, including alloiommunization, febrile reactions, viral infection and fraft-versus-host disease. There is a global drive towards implementing universal leukoreduction of platelet products on the day of collection. Filtration is currently the only method leukoreducing platelet products, but this technique results in only between 3 and 4-logs of leukocyte purging, is expensive and time-consuming, and may be difficult to implement on the day of platelet collection. We have demonstrated that PEFs of intermediate strength selectively purge leukocytes (>3-logs) and preserve platelet counts. We expect that more thorough leukoreduction (>5-logs) can easily be achieved using higher electric field strengths, without affecting platelet count and viability. We recently developed a flowing PEF apparatus for rapid treatment of clinical quantities of blood products. In phase I, this apparatus will be used to optimize operating parameters for leukoreduction. Levels of leukodepletion and platelet yield and viability will be critically assessed. Phase II will develop a PEF prototype apparatus for convenient and thorough leukodepletion on the day of collection, compatible with current platelet collection methodologies.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99974
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:99974\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SCIENCE RESEARCH LABORATORY, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOMERVILLE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02143
  • Organization District
    UNITED STATES